Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause

Current Opinion in Investigational Drugs

Volumn 10, Issue 1, 2009, Pages 75-90

  Pae, C U ^a,b   Park, M H ^a   Marks, D M ^b   Han, C ^b,c   Patkar, A A ^b   Masand, P S ^b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; ELLEFORE; MOXIFLOXACIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; WY 45233; WY 45494;

ANORGASMIA; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FIBROMYALGIA; HUMAN; HYPERHIDROSIS; INSOMNIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR DEPRESSION; MENOPAUSE; MYDRIASIS; NAUSEA; NEUROPATHIC PAIN; PULSE RATE; QT INTERVAL; REVIEW; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; TREMOR; VASOMOTOR DISORDER; VOMITING; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MENOPAUSE; MOLECULAR STRUCTURE; NEURALGIA; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VASOMOTOR SYSTEM;

EID: 58449120178     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. 675655 Wyeth submits two new drug applications for women's health therapies. Wyeth Pharmaceuticals PRESS RELEASE 2006 June 26
2. 732822 Wyeth reports earnings results for the 2006 third quarter and first nine months. Wyeth PRESS RELEASE 2006 October 19
3. max and AUC values were higher in ovariectomized female rats compared with intact males.
4. 778915 Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Deecher DC, Alfinito PD, Leventhal L, Cosmi S, Johnston GH, Merchenthaler I, Winneker R ENDOCRINOLOGY 2007 148 3 1376-1383
5. 782682 Annual report 2006 "Leading the way to a healthier world". Wyeth ANNUAL REPORT 2007 February 26
6. 815274 Wyeth receives approvable letter from FDA for Pristiq for the treatment of vasomotor symptoms associated with menopause. Wyeth Pharmaceuticals PRESS RELEASE 2007 July 24
7. 839919 Selegiline transdermal system: Current awareness and promise. Pae CU, Lim HK, Han CS, Neena A, Lee C, Patkar AA PROG NEURO PSYCHOPHARMACOL BIOL PSYCHIATRY 2007 31 6 1153-1163
8. 844470 Quarterly Report and results of operations for the three months and six months ended June 30, 2007. Wyeth FORM 10-Q 2007 August 07
9. 844472 Wyeth Q3 2007 earnings call. Wyeth COMPANY PRESENTATION 2007 October 18
10. 851875 Antidepressant agents for the treatment of chronic pain and depression. Jann MW, Slade JH PHARMACOTHERAPY 2007 27 11 1571-1587
11. 852579 A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA INT CLIN PSYCHOPHARMACOL 2007 22 6 338-347 • This paper disclosed data from a phase III clinical trial in outpatients with MDD (n = 375) treated with desvenlafaxine (200 or 400 mg/day po) for 8 weeks. At 8 weeks, adjusted mean change from baseline in HAM-D17 total score was greater for the desvenlafaxine doses than placebo and response rates were significantly superior at 60 and 56% for the 200- and 400-mg/day desvenlafaxine doses, respectively, compared with 38% for placebo. Remission rates were significantly improved at the 200-mg/day dose compared with placebo (37 versus 23%) but not 400-mg/day dose (34%).
12. 863365 Wyeth receives approvable letter from FDA for bazedoxifene for the prevention of postmenopausal osteoporosis. Wyeth Pharmaceuticals PRESS RELEASE 2007 December 24
13. 870579 Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms - A randomized controlled trial. Speroff L, Gass M, Constantine G, Olivier S, Study 315 Investigators OBSTET GYNECOL 2008 111 1 77-87 • The paper is the first publication of a phase III clinical trial with desvenlafaxine (50, 100, 150 and 200 mg/day po) administered to patients (n = 620) with menopausal vasomotor symptoms. The 75% responder rate was significantly greater for the 100-, 150- and 200-mg/day groups compared with placebo at week 4 (26.6, 38.0 and 33.3 versus 18.2%) and for the 100- and 200-mg/day groups at week 12 (49.7 and 45.0 versus 28.6%). The average daily severity of hot flushes was significantly lower in the 100- and 200-mg/day groups compared with placebo at week 12 (-31 and -27 versus -18%).
14. 873036 An assessment of drug-drug interaction: The effect of desvenlafaxine succinate and duloxetine on the pharmacokinetics of desipramine in healthy subjects. Patroneva A, Connolly S, Fatato P, Nichols A, Paul J, Guico-Pabia C INT J PSYCHIATRY CLIN PRACTICE 2007 11 4 334-335
15. 873203 Desvenlafaxine succinate versus placebo for prevention of depressive relapse in adult outpatients with major depressive disorder. Pitrosky B, Rickels K, Montgomery S, Tourian K, Guelfi JD, Padmanabhan SK, Germain JM, Leurent C, Brisard C INT J PSYCHIATRY CLIN PRACTICE 2007 11 4 335-336
16. 881847 FDA approves Pristiq for the treatment of adult patients with major depressive disorder. Wyeth PRESS RELEASE 2008 February 29
17. 882330 Form 10-K 2007 - Wyeth. Wyeth FORM 10-K 2008 February 29
18. 6 and VAS-PI compared with the placebo group.
19. 884805 Desvenlafaxine succinate (DVS) results in a sustained reduction in number of moderate-to-severe hot flushes (HFS). Muse K, Kirby L, Constantine G, Olivier S FERTIL STERIL 2007 88 Suppl 1 Abs P-420
20. 884807 Desvenlafaxine succinate (DVS), a novel serotonin and norepinephrine reuptake inhibitor, improves mood and menopausal symptoms in women with hot flushes (HFS) associated with menopause. Archer DF, DuPont C, Constantine G, Pickar J, Olivier S FERTIL STERIL 2007 88 Suppl 1 Abs P-422
21. 17 score was significantly greater in the 100- and 400-mg/day desvenlafaxine groups compared with placebo (-10.60 and -10.74 versus -7.65, respectively). Response rates were 51, 45 and 48% in the 100-, 200- and 400-mg/day dose groups, respectively, versus 35% for placebo and the remission rates were 30, 28 and 32% in the 100-, 200- and 400-mg/day dose groups, respectively, versus 19% for placebo.
22. 884815 Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH J PHARMACOL EXP THER 2006 318 2 657-665 • This paper is a comprehensive review of desvenlafaxine.
23. 884989 More clinical data required to support European approval of desvenlafaxine as a potential treatment for vasomotor symptoms. Wyeth PRESS RELEASE 2008 March 12
24. 885458 Wyeth Europa Ltd withdraws its marketing authorisation application for Pristiqs (desvenlafaxine). European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 March 12
25. 906044 Wyeth's Pristiq, a new treatment for major depressive disorder in adults, now available in US pharmacies. Wyeth PRESS RELEASE 2008 May 15
26. 906431 Pooled analysis of the safety and tolerability of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder. Clayton AH, Kornstein SG, Lamm L, Rosas G, Tourian KA EUR PSYCHIATRY 2008 23 Suppl 2 S201 • A pooled analysis of seven 8-week phase III clinical trials of desvenlafaxine administered as flexible doses (100 to 200 mg/day po) or fixed doses (100, 200 or 400 mg/day po) to patients with MDD (n = 2014) was undertaken. Adverse events were responsible for more discontinuations in the pooled desvenlafaxine groups compared with placebo (15 versus 4%). In the fixed-dose trials, discontinuation rates increased with dose; no differences were reported based on gender. Mild nausea was the most common treatment-emergent adverse event, with a duration of approximately 6 days; incidence decreased to placebo levels within 1 week.
27. 908148 An integrated analysis of the efficacy of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder. Thase ME, Kornstein SG, Tummala R, Germain JM, Jiang Q, Ahmed S, Ninan PT EUR PSYCHIATRY 2008 23 Suppl 2 S208
28. 908220 Reduction of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine succinate: A pooled analysis. Tourian KA, Ahmed S, Patroneva A, Zitek B, Graepel J, Pitrosky B EUR PSYCHIATRY 2008 23 Suppl 2 S208
29. 909003 Desvenlafaxine succinate efficacy in improving functional outcomes and pain in younger, midlife, and older women and men with major depression. Scares CN, Thase ME, Kornstein SG, Brisard C, Septien-Velez L, Germain JM, Pitrosky B, Patroneva A, Zitek B, Jiang Q, Ninan P EUR PSYCHIATRY 2008 23 Suppl 2 S263-S264
30. 923719 A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B INT CLIN PSYCHOPHARMACOL 2008 23 4 188-197
31. 6 and VAS-PI versus placebo.
32. 936364 Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Utian WH HEALTH QUALITY LIFE OUTCOMES 2005 3 47
33. 936422 Health care-seeking for menopausal problems. Guthrie JR, Dennerstein L, Taffe JR, Donnelly V CLIMACTERIC 2003 6 2 112-117
34. 936434 Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW AM J THER 2003 10 5 318-323
35. 936441 Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Deecher DC EXPERT OPIN INVEST DRUGS 2005 14 4 435-448
36. 936469 A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ ARTHRITIS RHEUM 2004 50 9 2974-2984
37. 936470 A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF PAIN 2005 119 1-3 5-15
38. 936471 A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG HUM PSYCHOPHARMACOL 2004 19 Suppl 1 S27-S35
39. 936472 Efficacy of milnacipran in patients with fibromyalgia. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ J RHEUMATOL 2005 32 10 1975-1985
40. 936473 Desvenlafaxine succinate for the treatment of major depressive disorder. Lohoff FW, Rickels K EXPERT OPIN PHARMACOTHER 2008 9 12 2129-2136 • This paper is a comprehensive review of desvenlafaxine.
41. 936856 Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association AM J PSYCHIATRY 2000 157 4 Suppl 1-45
42. 936858 Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K et al AM J PSYCHIATRY 2006 163 1 28-40
43. 936859 New formulations of existing antidepressants: Advantages in the management of depression. Norman TR, Olver JS CNS DRUGS 2004 18 8 505-520
44. 936860 Paroxetine: Current status in psychiatry. Pae CU, Patkar AA EXPERT REV NEUROTHERAPEUTICS 2007 7 2 107-120
45. 936863 Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion. Pae CU, Lim HK, Han C, Patkar AA, Steffens DC, Masand PS, Lee C EXPERT REV NEUROTHERAPEUTICS 2007 7 10 1251-1263
46. 936864 Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ J CLIN PSYCHOPHARMACOL 2007 27 6 672-676
47. 936865 Ethnicity/race and outcome in the treatment of depression: Results from STAR*D. Lesser IM, Castro DB, Gaynes BN, Gonzalez J, Rush AJ, Alpert JE, Trivedi M, Luther JF, Wisniewski SR MED CARE 2007 45 11 1043-1051
48. 936869 Duloxetine: A new psychopharmacologic treatment option for fibromyalgia? Pae CU, Masand P CURR PSYCHIATRY REP 2008 10 3 237-239
49. 936870 Clinical experience with dual action antidepressants in different chronic pain syndromes. Briley M HUM PSYCHOPHARMACOL 2004 19 Suppl 1 S21-S25
50. 943372 Identifying meaningful differences in vasomotor symptoms among menopausal women. Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD MENOPAUSE 2008 15 4 Pt 1 698-705
51. 943375 Efficacy, safety and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA INT CLIN PSYCHOPHARMACOL 2008 23 5 243-253
52. 943383 The effects of desvenlafaxine succinate and paroxetine on the pharmacokinetics of desipiramine in healthy adults. Patroneva A, Nichols AI, Fatato P, Shenouda M, Pedersen RD, Jiang Q, Ahmed S EUR NEUROPSYCHOPHARMACOL 2007 17 Suppl 4 AbsP-2-d-015
53. 943384 A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects. Preskorn S, Patroneva A, Nichols A, Silman H, Pedersen R, Paul J, Ahmed S EUR NEUROPSYCHOPHARMACOL 2007 17 Suppl 4 AbsP-2-b-013
54. 944146 Desvenlafaxine succinate (DVS) efficacy for the relief of vasomotor symptoms (VMS) associated with menopause: A double-blind, placebo-controlled trial. Archer DF, Seidman L, Constantine G, Pickar J, Olivier S FERTIL STERIL 2007 88 Suppl 1 Abs P-413
55. 944365 Comparing the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects who are extensive and poor metabolizers via cytochrome P450 (CYP) 2D6. Preskorn S, Patroneva A, Nichols A, Silman H, Pedersen R, Paul J, Ahmed S NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs I-16
56. 944366 The effects of desvenlafaxine succinate and paroxetine on the pharmacokinetics of desipramine in healthy adults. Patroneva A, Nichols A, Fatato P, Shenouda M, Paul J, Pedersen RD, Jiang Q, Ahmed S NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs I-17
57. 944367 Safety, pharmacokinetics (pk) and pharmacodynamics (pd) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects. Parks V, Patat A, Behrle J, Parker V, Decours J AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PI-75
58. 944368 A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine succinate in outpatients with major depressive disorder. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK, Entsuah R ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR299
59. 944369 An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. Kornstein SG, Thase ME, Tummala R, Germain J-M, Jiang Q, Ninan PT, Guico-Pabia C ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-125
60. 944370 Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine succinate or placebo. Patroneva A, Kornstein SG, Fava M, Jiang Q, Ahmed S ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-082
61. 944371 Assessing the efficacy of desvenlafaxine for improving functioning and quality of life measures in patients with major depressive disorder. Soares CN, Thase ME, Kornstein SG, Brisard C, Septien-Velez L, Germain J-M, Pitrosky B, Patroneva A, Jiang Q, Ninan PT ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-089
62. 944372 A 12-month open-label evaluation of long-term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder. Ferguson JM, Tourian KA, Rosas GR, Padmanabhan SK, Entsuah R ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR344
63. 944373 Desvenlafaxine improves mood in women treated for vasomotor symptoms: Effect of baseline mood states. Steiner M, Kirby L, Yu H, Bobula J, Oliver S ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR705
64. 944374 Symptom reduction in women treated with desvenlafaxine for menopausal hot flushes: Impact of bothersomeness. Steiner M, Soares CN, Kirby L, Yu H, Bobula J, Oliver S ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR713
65. 944375 Treating the painful physical symptoms of depression with desvenlafaxine succinate versus placebo in depressed outpatients. Brisard C, Zitek BE, Ninan PT, Germain J-M, Ahmed S, Padmanabhan SK, Yeung PP ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR365
66. 944376 Improvement of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine: A pooled analysis. Ahmed S, Patroneva A, Graepel J, Pitrosky B ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR3-145
67. 944377 Improvement of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine succinate: A pooled analysis. Tourian KA, Ahmed S, Patroneva A, Zitek B, Graepel J, Pitrosky B ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR366
68. 944378 Efficacy following switch from venlafaxine to desvenlafaxine in responders versus nonresponders. Guico-Pabia C, Ahmed S, Jiang Q, Patroneva A, Ninan PT, Thase ME ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-088
69. 944379 Switch from venlafaxine to desvenlafaxine succinate is well tolerated in patients with major depressive disorder. Ahmed S, Zitek B, Ninan PT, Pitrosky B, Rosas G, Jiang Q, Tummala R ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR363
70. 944380 Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Montgomery SA, Fava M, Tourian KA, Padmanabhan SK, Guico-Pabia C ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-038
71. 944381 Pooled analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Clayton A, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-083
72. 944382 Blood pressure changes with fixed-dose desvenlafaxine succinate: Pooled results from five placebo-controlled, studies in depressed outpatients. Thase ME, Guico-Pabia C, Tourian KA ANN MEET AM PSYCHIATR ASSOC 2008 161 May 03-08 Abs NR5-036
73. 944384 A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder. Rickels K, Montgomery SA, Guelfi JD, Tourian KA, Pitrosky B, Padmanabhan SK, Germain J-M ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs NR327
74. 944385 Efficacy of desvenlafaxine succinate 50 mg/d and 100 mg/d: Results from two placebo-controlled, fixed-dose studies in depressed outpatients. Liebowitz M, Montgomery S, Boyer P, Manley AL, Padmanabhan SK, Tummala R, Germain J-M, Brisard C, Tourian KA ANN MEET AM PSYCHIATR ASSOC 2007 160 May 19-24 Abs 41
75. 944387 Efficacy and safety of desvenlafaxine succinate in the treatment of MDD. DeMartinis N, Yeung P, Entsuah R ANN MEET AM PSYCHIATR ASSOC 2006 159 May 20-25 Abs 101
76. 944388 Randomized, double-blind, placebo-controlled study of desvenlafaxine succinate in MDD. Septien-Velez L, Pitrosky B ANN MEET AM PSYCHIATR ASSOC 2006 159 May 20-25 Abs NR284
77. 944389 Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. DeMartinis N, Yeung PP, Entsuah R ANN MEET AM PSYCHIATR ASSOC 2006 159 May 20-25 Abs NR487
78. 944390 Double-blind, placebo- and moxifloxacin-controlled crossover study of the effects of desvenlafaxine succinate on QT interval in healthy adult female subjects. Paul J, Behrle JA, Richards LS, Menton R, Nichols AI, Posener JA ANN MEET AM PSYCHIATR ASSOC 2006 159 May 20-25 Abs NR571
79. 944391 Safety, pharmacokinetics (ZCASEPK) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects. Parks V, Patat A, Behrle JA, Troy SM, Decours JH AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PI-141
80. 944392 The absolute bioavailability of an oral sustained-release formulation of desvenlafaxine duccinate in healthy subjects. Parker VD, Richards LS, Nichols AI, Behrle JA, Fruncillo RJ AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PI-149
81. 944393 An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Behrle JA, Nichols AI, McGrory SB, Raible D AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PII-122
82. 944394 An ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Richards LS, Behrle JA, Nichols AI, Fruncillo RJ, Paul J AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PII-130
83. 944395 An open-label, randomized, crossover study of the relative bioavailability of desvenlafaxine after oral administration of extended-release venlafaxine and sustained-release desvenlafaxine succinate in healthy subjects. Nichols AI, Patat A, Baird-Bellaire S, Behrle JA, Chretien P AM SOC CLIN PHARMACOL THER ANN MEET 2005 March 02-05 Abs PII-137
84. 944396 Bioavailability and pharmacokinetics of desvenlafaxine succinate extended release: Effects of food. Richards LS, Plotka A, Behrle JA, Posener JA, Nichols AI AM SOC CLIN PHARMACOL THER ANN MEET 2006 March 08-11 Abs PI-68
85. 944397 Effects of chronic hepatic impairment on the pharmacokinetics and safety of desvenlafaxine succinate extended release. Baird-Bellaire S, Patat AA, Fauchoux N, Reh C, Nichols AI, Behrle JA AM SOC CLIN PHARMACOL THER ANN MEET 2006 March 08-11 Abs PI-73
86. 944398 Lack of clinically relevant effect of pharmacokinetic interaction between ketoconazole and desvenlafaxine-SR pharmacokinetics. Patat A, Baird-Bellaire S, Behrle J, Chandra P, Nichols AI AM SOC CLIN PHARMACOL THER ANN MEET 2007 March 21-24 Abs PII-50
87. 944399 The efficacy of desvenlafaxine for improving functioning and quality of life measures in patients with major depressive disorder. Soares C, Thase M, Kornstein S, Brisard C, Septien-Velez L, Germain JM, Pitrosky B, Patroneva A, Jiang Q, Ninan P, Ganguly R EUR NEUROPSYCHOPHARMACOL 2008 18 Suppl 4 Abs P.2.c.033
88. 944400 An analysis by age and gender of efficacy data from placebo-controlled desvenlafaxine succinate clinical trials in depressed outpatients. Kornstein SG, Clayton AH, Soares C, Thase ME, Brisard C, Pitrosky B, Jiang Q, Ahmed S NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs I-18
89. 944401 A multicenter, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder. Rickels K, Montgomery S, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain J-M, Leurent C, Brisard C NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs I-28
90. 944402 Assessing the efficacy of desvenlafaxine succinate for improving functioning, well-being, and pain in younger, midlife, and older women and men with major depression. Soares C, Thase M, Kornstein S, Brisard C, Septien-Velez L, Germain J-M, Pitrosky B, Patroneva A, Zitek B, Jiang Q, Ninan P NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs I-33
91. 944403 Reduction of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine succinate: A pooled analysis. Tourian K, Ahmed S, Patroneva A, Zitek B, Graepel J, Pitrosky B NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs II-2
92. 944404 An integrated analysis of the efficacy of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder. Thase ME, Kornstein SG, Yeung PP, Tummala R, Germain J-M, Maio P, Jiang Q, Ahmed S, Ninan PT NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs II-88
93. 944405 A pooled analysis of the safety and tolerability of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder. Clayton A, Kornstein S, Lamm L, Rosas G, Tourian KA NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs II-89
94. 944406 Desvenlafaxine succinate vs. placebo for the treatment of the painful physical symptoms of depression. Brisard C, Zitek B, Ninan PT, Germain J-M, Ahmed S, Padmanabhan SK, Leurent C, Yeung PP NEW CLIN DRUG EVAL UNIT ANNU MEET 2007 47 June 11-14 Abs II-95
95. 952647 Wyeth provides regulatory update regarding desvenlafaxine for the treatment of major depressive disorder. Wyeth Pharmaceuticals PRESS RELEASE 2008 October 15
96. 952906 Wyeth Europa Ltd withdraws its marketing authorisation application for Ellefore. Wyeth PRESS RELEASE 2008 October 15
97. 957614 Wyeth Q3 2008 earnings conference call. Wyeth Company Presentation 2008 October 22
98. 960048 An assessment of drug-drug interactions: The effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Patroneva A, Connolly S, Fatato P, Pedersen R, Jiang Q, Paul J, Guico-Pabia C, Isler JA, Burczynski ME, Nichols A DRUG METAB DISPOS 2008 36 12 2484-2491
99. 960357 A multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of DVS-233 SR and venlafaxine ER in adult outpatients with major depressive disorder. Synopsis based on final report (Protocol 3151A1-317). Wyeth COMPANY PUBLICATION 2005 October 19
100. 960378 A multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of DVS SR and venlafaxine ER in adult outpatients with major depressive disorder. Synopsis based on final report (Protocol 3151A1-309). Wyeth COMPANY PUBLICATION 2005 October 26
101. 960503 A muticenter, randomized, double-blind, placebo-controlled, duloxetine-referenced, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (50mg, 100mg) of desvenlafaxine sustained-release tablets in adult outpatients with major depressive disorder. Synopisis based on final report (Protocol 3151A1-335). Wyeth COMPANY PUBLICATION 2008 March 24
102. 960554 A 10-month, open-label evaluation of the long-term safety of DVS SR in outpatients with major depressive disorder. Synopsis based on final report (Protocol 3151A1-303). Wyeth COMPANY PUBLICATION 2008 March 21
103. 960558 A 6-month,open-label evaluation of the long-term safety of DVS-233 SR in elderly outpatients with major depressive disorder. Synopsis based on final report (Protocol 3151A1-307). Wyeth COMPANY PUBLICATION 2008 April 05
104. 960569 Highlights of prescribing information: Pristiq (desvenlafaxine) extended-release tablets, oral. Wyeth DRUG PACKAGE INSERT 2008 April 30
105. 960579 Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, SS duloxetine, paroxetine, sertraline and bupropion on human cytochrome P450 activities. Shilling A, Young-Sciame R, Leung L INT SOC STUDY XENOBIOTIC 2005 13 October 25-27